Through a combination of organic growth and acquisitions in the sectors of contract development & manufacturing services (CDMO) and complicated generics, Piramal Pharma stated that it would concentrate on scaling up its operations and increasing its margins.
A division of Piramal Enterprises produced Piramal Pharma. On October 19, its shares were listed on stock exchanges. On a recent interview with ET, Piramal Pharma chair Nandini Piramal stated that the business would invest Rs 1,200 crore in antibody drug conjugate capacity at Grangemouth, the UK, over the course of the following 12 to 18 months. In addition to increasing capacity at its API facilities in India and for potent injectables at Lexington in the US, it is also looking to increase capacity at Riverview in the US for active pharmaceutical ingredients.